Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Zhejiang Huahai Pharmaceutical Co., Ltd.
483
•Zhejiang Huahai Pharmaceutical Co., Ltd.•April 24, 2026

Zhejiang Huahai Pharmaceutical Co., Ltd. – FDA 483, Apr 24, 2026

Record Details

Between April 13 and April 24, 2026, the U.S. Food and Drug Administration (FDA) conducted an inspection of the facility associated with FEI 3003999190, managed by Linda Lin, Vice President of Quality and Regulatory Affairs. This inspection resulted in the issuance of a Form 483, which outlines preliminary observations concerning potential deviations from established quality standards and safety regulations. The primary violation identified during the inspection involves the firm"s failure to document investigations into production discrepancies. Specifically, the facility did not maintain written records regarding the failure of batches or specific components to meet predetermined quality specifications. Under the federal regulatory framework for manufacturing, such investigations are mandatory to ensure that any issues affecting product integrity are identified, analyzed, and resolved. While the Form 483 does not represent a final determination of non-compliance, it requires the firm to take immediate action. The company is expected to review the observations and submit a formal response to the FDA. This response must include a detailed corrective action plan outlining how the facility will improve its documentation processes and ensure all future manufacturing failures are thoroughly investigated and recorded. Timely and effective remediation is necessary to demonstrate compliance and ensure the ongoing safety of the products manufactured at this site.

Company
Zhejiang Huahai Pharmaceutical Co., Ltd.
Inspection date
April 24, 2026
Product type
drugs
Office
Office of Inspections and Investigations
People
  • Marcellinus D. Dordunoo (Investigator)
  • Dipesh K. Shah
  • Eileen A. Liu
View Company Profile

ID · b8364697-ffce-40cd-a7e7-ba3650f1c806

Other documents for Zhejiang Huahai Pharmaceutical Co., Ltd.
  • 483 - 2025-04-16April 16, 2025
  • WARNING_LETTER - 2025-01-24January 24, 2025
  • 483 - 2025-01-24January 24, 2025
  • 483 - 2019-06-28June 28, 2019
  • 483 - 2019-05-31May 31, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Zhejiang Huahai Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.